

ACTA MEDICINAE Speciál 2012 GYNEKOLOGIE

Kompletní literatura

- 2 **Novinky v hormonální antikoncepci**
MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 2 **Inkontinence moči u žen**
prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha
- 2 **Hyperaktivní močový měchýř u žen**
prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha
- 3 **Možnosti biologické léčby karcinomu ovaria**
MUDr. Zdeněk Adamík, Ph.D. Gynekologicko-porodnické oddělení KNTB, a. s., Zlín, Univerzita Tomáše Bati, Zlín
MUDr. Barbora Kováčová Gynekologicko-porodnické oddělení KNTB, a.s., Zlín
- 3 **Endometrióza – význam včasné diagnostiky, novinky v léčbě**
MUDr. Hana Hrušková Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
- 4 **Výhody gestagenní antikoncepce**
MUDr. Jiří Dvořák Klinika nemocí plicních a TBC LF MU a FN Brno

Novinky v hormonální antikoncepci

MUDr. Michael Fanta, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Meade, T. W. – Greenberg, G. – Thompson, S. G.: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. *Br Med J*, 1980, 280, s. 1157–1161.
- 2 Fanta, M.: Kombinovaná hormonální antikoncepce. *Postgraduální medicína*, 2009, 11, 4, s. 247–250.
- 3 Fanta, M.: Novinky v hormonální antikoncepci. *Lékařské listy*, 2009, 9, s. 26–28.
- 4 Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet*, 2008, 371 (9609), s. 303–314.
- 5 Hannaford, P. C.: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study. *BMJ*, 2007, 335, s. 651.
- 6 Pearlstein, T. B. – Bachmann, G. A. – Zacur, H. A., et al.: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. *Contraception*, 2005, 72 (6), s. 414–421.
- 7 Yonkers, K. A. – Brown, C. – Pearlstein, T. B., et al.: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol*, 2005, 106 (3), s. 492–501.
- 8 Parke, S.: Bleeding patterns and cycle control with a novel four-phasic COC containing estradiol valerate and dienogest + Efficacy and tolerability of an innovative four-phasic COC containing estradiol valerate and dienogest. 10th Congress of ESC, 2008.
- 9 Eu, J.: Contraception Reprod HealthCare, *Book of Abstracts*, roč. 15, dopl. 1, 11th Congress of ESC, květen 2010.
- 10 Sulak, P. J. – Scow, R. D. – Preece, C., et al.: Hormone withdrawal symptoms in oral contraceptive users. *Obstet Gynecol*, 2000, 95, s. 261–266.
- 11 Creinin, M. D.: Multicenter comparison of contraceptive ring and patch: randomized controlled trial. *Obstet Gynecol*, 2008, 111, s. 266–277.
- 12 *Medical Eligibility for Contraceptive Use*, 4. vydání, 2010, dostupné z: www.who.int/reproductivehealth.
- 13 Čepický, P. – Cibula, D., et al.: Doporučení k předpisu kombinované hormonální antikoncepce, aktualizace 2005. *Čes Gynekol*, 2005, 70, s. 465–468.
- 14 Westhoff, C., et al.: Efficacy, safety, and tolerability of a monophasic oral contraceptive containing norgestrel acetate and 17 β -estradiol: a randomized controlled trial. *Obstet Gynecol*, 2012, 119, s. 989–999.

Inkontinence moči u žen

prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha

- 1 Abrams, P. – Cardoso, L. – Fall, M., et al.: The standardization of Terminology of Lower Urinary Tract Function: report from the Standardization Subcommittee of the International Continence Society. *Neurourol Urodyn*, 2002, 1, s. 167–178.
- 2 Debodiance, P. – Delporte, P.: MiniArc: preliminary prospective study on 72 cases. *J Gynecol Obstet Biol Reprod*, 2009, 38 (2), s. 144–148.
- 3 DeLeval, J.: Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal tape inside-out. *Eur Urol*, 2003, 44, s. 724–730.
- 4 DeLeval, J. – Thomas, A. – Waltregny, D.: The original versus a modified inside-out transobturator procedure: 1-year results of a prospective randomized trial. *Int Urogynecol J*, 2010, 22 (2), s. 145–156.
- 5 Flock, F. – Reich, A. – Muche, R., et al.: Hemorrhagic complications associated with tension-free vaginal tape procedure. *Obstet Gynecol*, 2004, 104, s. 989–999.
- 6 Kuuva, N. – Nilsson, C. G.: A national analysis of complications associated with the tension-free vaginal tape procedure. *Acta Obstet Gynecol Scand*, 2002, 81, s. 72–77.
- 7 Martan, A. – Švábík, K. – Halaška, M., et al.: Vyhodnocení prvních zkušeností s bezpečností a krátkodobým efektem mini-páskových antiinkontinentních operací MiniArc a AJUST. *Čes Gynekol*, 2011, 76, s. 349–355.
- 8 Meshia, M. – Barbacini, P. – Barbacini, R., et al.: Short-term outcomes with the AJUSTTM system: a new single incision sling for the treatment of stress urinary incontinence. *Int Urogynecol J*, 2011, 22, s. 177–182.
- 9 Nilsson, C. G. – Falconer, C. – Rezapour, M.: Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. *Int Urogynecol J*, 2008, 19, s. 1043–1047.
- 10 Richter, H. E. – Albo, M. E. – Zyczynski, H. M., et al.: Retropubic versus transobturator midurethral slings for stress incontinence. *N Engl J Med*, 2010, 362, s. 2066–2076.
- 11 Ulmsten, U. – Petros, P.: Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence. *Scand J Urol Nephrol*, 1995, 29, s. 75–82.
- 12 Waltregny, D. – Gaspar, Y. – Reul, O., et al.: TVT-O for the treatment of female stress urinary incontinence: Results of a prospective study after a 3-year minimum follow-up. *Euro Urol*, 2008, 53, s. 401–410.

Hyperaktivní močový měchýř u žen

prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha

- 1 Abrams, P. – Cardov, L. – Fall, M., et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. *Neurourol Urodyn*, 2002, 21, s. 167–178.
- 2 Hannestad, Y. S. – Rortveit, G. – Sandvik, H., et al.: A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT Study. *J Clin Epidemiol*, 2000, s. 1150–1157.
- 3 van Kerrebroek, P. – Abrams, P. – Chaikin, D., et al.: The standardisation of terminology in nocturia: report from the Standardisation Subcommittee of the International Continence Society. *Neurourol Urodyn*, 2002, 21, s. 179–183.
- 4 Milsom, I. – Abrams, P. – Cardov, L., et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int*, 2001, 87, s. 760.
- 5 Irwin, D. E. – Milsom, I. – Hunskaar, S., et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries; results of EPIC study. *Eur Urol*, 2006, 50 (6), s. 1306–1314.

- 6 McGrother, C. W. – Donaldson, M. M. – Shaw, C., et al.: MRC Incontinence Study Team Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. *BJU Int*, 2004, 93 (6), s. 763.
- 7 Stewart, W. F. – Corey, R. – Herzog, A. R., et al.: Prevalence of overactive bladder in women: results from the NOBLE program. *Int Urogynaecol J*, 2001, 12 (3), S66.
- 8 Martan, A. – Horčíčka, L. – Hanuš, T., et al.: Prevalence žen s hyperaktivním močovým měchýřem v České republice. *Čes Gynek*, 2011, 76, s. 144–150.

Možnosti biologické léčby karcinomu ovaria

MUDr. Zdeněk Adamík, Ph.D.

Gynekologicko-porodnické oddělení KNTB, a. s., Zlín, Univerzita Tomáše Bati, Zlín

MUDr. Barbora Kováčová Gynekologicko-porodnické oddělení KNTB, a.s., Zlín

- 1 Fischerová, D. – Zikán, M. – Pinkasová, I. – Sláma, J. – Fruhauf, F. – Freitag, P. – Dundr, P. – Burgetová, A. – Cibula, D.: Racionální předoperační diagnostika benigních a maligních ovariálních nádorů – zobrazovací metody, nádorové markery. *Česká gynekologie*, 2012, 77, 4, s. 272–287.
- 2 Campos, S. M. – Ghosh, S.: A current review of targeted therapeutics for ovarian cancer. *Journal of Oncology*, 2010, Article ID 149362, s. 11.
- 3 Berek, J. S. – Schultes, B. C. – Nicodemus, Ch. F.: Biologic and immunologic therapies for ovarian cancer. *Journal of Clinical Oncology*, 2003, 21, s. 168–174.
- 4 Mountzios, G. – Soria, J. Ch.: Overview of existing therapies. In: Giaccone, G. – Soria, J. Ch.: *Targeted therapies in oncology*. New York, Informa healthcare, 2007, s. 1–4.
- 5 Gabra, H. on behalf of the AS1404-202 Study Group Investigators: Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. *J Clin Oncol*, 2006, 24 (dopl.), s. 263 (abstrakt 5032).
- 6 Rini, B. I.: Temsirolimus, an inhibitor of mammalian target of rapamycin. *Clin Cancer Res*, 2008, 14, s. 1286–1290.
- 7 Shih, I. M. – Ho, Ch. M. – Nakayama, K. – Salani, R.: Pathogenesis and new therapeutic targets of ovarian cancer. *Journal of Oncology*, 2012, Article ID 867512, 2s.
- 8 Bast, R. C. jr. – Hennessy, B. – Mills, G. B.: The biology of ovarian cancer: new opportunities for translation. *Nat Rev Cancer*, 2009, 9 (6), s. 415.
- 9 Rose, S. L.: *Biologic therapies in ovarian cancer*. Advances in Research Gynecologic Oncology Program 2007, www.uwhealth.org/83CC4280-CF3C-4377-9410-D2A8FB4499AD/FinalDownload/DownloadId-A144F8ACD5A1790FC0EBBE40C11A4DAC/83CC4280-CF3C-4377-9410-D2A8FB4499AD/files/uwhealth/docs/pdf/gynonc_Fall20071.pdf, vyhledáno 3. 10. 2012.
- 10 Honová, H.: *Biologická léčba v onkologii*, ZdN, <http://zdravi.e15.cz/clanek/postgraduální-medicína/biologická-lechba-v-onkologii-414583>. (citace 11. 3. 2009).
- 11 Rusňák, I. – Štencl, J.: *Ultrazvuková diagnostika ovariálních nádorů*. Bratislava, Nadácia Vznik a zdravý vývoj plodu, 1995, s. 11–12.

Endometrióza – význam včasné diagnostiky, novinky v léčbě

MUDr. Hana Hrušková Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

- 1 Barnard, N. D. – Scialli, A. R. – Hurlock, D. – Bertron, P.: Diet and sex-hormone binding globulin dysmenorrhoea and premenstrual symptoms. *Obstet Gynecol*, 2000, 95, s. 245–250.
- 2 Crosignani, P. – Olive, D. – Bergqvist, A. – Luciano, A.: Advances in the management of endometriosis: an update for clinicians. *Hum Reprod Update*, 2006, 12, s. 179–189.
- 3 Deutch, B. et al.: Menstrual discomfort in Danish women reduced by dietary supplements of omega-3 PUFA and B12 (fish oil or seal oil capsules). *Nutrition Research*, 2000, 20, s. 621–631.
- 4 Giudice, L. C. – Swiersz, L. M. – Burney, R. O.: Endometriosis. In: Jameson, J. L. – De Groot, L. J. eds.: *Endocrinology*. New York, Elsevier, 2010, s. 2356–2370.
- 5 Guo, S. W.: Recurrence of endometriosis and its control. *Hum Reprod Update*, 2009, 15, s. 441–461.
- 6 Otkán, S. – Murk, W. – Arici, A.: Endometriosis and infertility: epidemiology and evidence-based treatments. *Ann NY Acad Sci*, 2008, 1127, s. 92–100.
- 7 Parazzini, F. – Chiaffarino, F. – Surace, M. – Chatenoud, L. – Ciprian, S. – Chiantera, V. – Benzi, G. – Fedele, L.: Selected food intake and risk of endometriosis. *Hum Reprod*, 2004, 19 (8), s. 1755–1759.
- 8 Practice Committee of the American Society for Reproductive medicine. Endometriosis and infertility. *Fertil Steril*, 2006, 86, dopl., s. S156–S160.
- 9 Sagsveen, M. – Farmer, J. E. – Prentice, A. – Breeze, A.: Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. *Cochrane Database Syst Revs*, 2003, 4, CD001297.
- 10 Selak, V. – Farquhar, C. – Prentice, A. – Singla, A. A.: Danazol for pelvic pain associated with endometriosis. *Cochrane Database of Systematic Reviews*, 2007, 4, CD000068.
- 11 Sirois, J. – Richards, J. S.: Purification and characterisation of a novel, distinct, isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. *J Biol Chem*, 1992, 267, s. 6382–6388.
- 12 Stekkinger, E. – van der Linden, P. J.: A levonorgestrel-containing IUD for the treatment of endometriosis. *Ned Tijdschr Geneesk*, 2007, 151 (43), s. 2372–2376.
- 13 The Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. *Fertil Steril*, 2008, 90, s. S260–S269.
- 14 Vercellini, P. – Frantino, G. – De Giorgi, O. – Pietropaolo, G. – Pasin, R. – Crosignani, P. G.: Continuous use of an oral contraceptive for endometriosis – associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. *Fertil Steril*, 2003, 80, s. 560–563.
- 15 Overton, C. – Davis, C. – McMillan, L. – Shaw, R. W.: *An Atlas of endometriosis*. The Parthenon Publishing Group, Londýn, 2002, s. 58–88.

Výhody gestagenní antikoncepce

MUDr. Jiří Dvořák Klinika nemocí plicních a TBC LF MU a FN Brno

- 1 Čepický, P. – Líbalová Z.: *Moderní babičtví*, 2008, 15.
- 2 SPC Azalia.
- 3 SPC Cerazette.
- 4 SPC Mirena.
- 5 Čepický, P. – Cibula, D. – Dvořák, K. – Dvořák, V. – Hlaváčková, O. – Košťál, M. – Líbalová, U. – Makalová, D. – Rokyta, Z. – Unzeitig, V. – Uzel, R. – Živný, J.: Doporučení k předpisu kombinované hormonální antikoncepce. *Česká gynekologie*, 2005, 70, s. 324–328.